MarketPulse

NDA deficiencies

4 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Portnoy Law Firm

Aquestive Faces Class Action Over Anaphylm Drug Approval Misstatements

Portnoy Law Firm files class action against Aquestive Therapeutics for allegedly misleading investors about Anaphylm drug approval prospects, citing undisclosed FDA deficiencies.
AQSTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Portnoy Law Firm

Aquestive Therapeutics Hit by Class Action Over FDA Anaphylm Disclosure Failures

Portnoy Law Firm files class action against Aquestive Therapeutics for allegedly failing to disclose FDA deficiencies in Anaphylm NDA, causing 37% stock decline.
AQSTclass action lawsuitstock decline
GlobeNewswire Inc.GlobeNewswire Inc.··Portnoy Law Firm

Aquestive Therapeutics Faces Class Action Over Anaphylm FDA Approval Misstatements

Portnoy Law Firm files class action against $AQST for allegedly misleading investors about Anaphylm FDA prospects. Stock plunged 37% after deficiency disclosure.
AQSTsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Faruqi & Faruqi, Llp

AQST Stock Plunged 37% After FDA Setback; Securities Lawsuit Deadline Looms May 4

Aquestive Therapeutics faces securities class action over alleged false FDA approval statements for Anaphylm drug. Stock fell 37% after January 2026 NDA rejection.
AQSTsecurities class actionmisleading statements